Friday August 19 2011 11:32 AM
People who support PwMS wanted to review a new handbook.
Trinity College Dublin is looking for people who support people with multiple sclerosis (MS) to review a handbook and answer a questionnaire based on the content. The study aims to determine if a change in the way in which neurology nurse specialists provide support to people who support people with MS results in better care outcomes for the person diagnosed with MS and their support person. For the purpose of this study a support person is defined as a person who provides the most support or physical assistance to a person with MS, and who is not a paid service provider.
Title of study: An Exploratory Randomised Controlled Trial of a Manualised, Nurse-led, Telephone Intervention Support Service for People who Support People with MS.
The researcher is seeking help from people who support people with MS in providing expert review on a booklet, designed as part of an overall problem management intervention for people who support people with MS. The overall purpose of the study that I am carrying out is to determine if a change in the way in which neurology nurse specialists provide support to people who support people with multiple sclerosis (MS) results in better care outcomes for the person diagnosed with MS and their support person.
The Faculty of Health Sciences Ethics Committee Trinity College Dublin have given approval for this study to be carried out and medical and nursing access has been obtained to carry out the study.
Participating in this phase of the study involves reading the guidebook and completing a questionnaire to evaluate its content. I will then analyse the results provided along with that of other experts who have been invited to partake in this part of the study and make any adjustments necessary for the use of this guidebook for the purpose of this study.
If you are interested in the study please contact Margarita Corry at macorry@tcd.ie or phone 087 368 3557 / 087 907 7831. All relevant material can be emailed or posted.
Download official invite

Comments
Ana Aitawa
Monday August 14 2017 12:35
We have recently published a research study on global Multiple Sclerosis Treatment market segmented by Drug Class (Brand) – Alemtuzumab (Lemtrada), Dimethyl Fumarate (Tecifidera), Gilneya (Fingolimod), Glatiramer Acetate (Copaxone), Interferon-β1a (Avonex), Interferon-β1a (Rebif), Interferon-β1b (Betaseron/Extavia), Natalizumab (Tysabri), Peginterferon-β1a (Plegridy), Teriflunomide (Aubagio), Clinical Pipeline (Phase III) – Daclizumab (Zinbryta), Ocrelizumab (Ocrevus), Ozanimod (RPC-1063). The analysis estimates the global Multiple Sclerosis Treatment market to reach nearly US$ 22.8Billion by 2021, growing at 0.7%CAGR over 2017-2021 forecast period. For more details, visit https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/